Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With CNS AT/RT
NCT00084838Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2003
- Primary completion
- Feb 2008
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, actinomycin D, cyclophosphamide, cisplatin, doxorubicin and 5 more in Atypical teratoid rhabdoid tumor (ATRT), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Overall Survival at 2 years. Started Feb 2003; status: completed.
02
Drugs
vincristineactinomycin Dcyclophosphamidecisplatindoxorubicin
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT00084838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084838.